Lantern Pharma Correlations
LTRN Stock | USD 3.72 0.03 0.80% |
The current 90-days correlation between Lantern Pharma and Generation Bio Co is -0.06 (i.e., Good diversification). A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lantern Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lantern Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction.
Lantern Pharma Correlation With Market
Average diversification
The correlation between Lantern Pharma and DJI is 0.1 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Lantern Pharma and DJI in the same portfolio, assuming nothing else is changed.
Lantern |
Moving together with Lantern Stock
0.77 | OPT | Opthea | PairCorr |
0.68 | INGN | Inogen Inc | PairCorr |
0.74 | NPCE | Neuropace | PairCorr |
0.64 | NYXH | Nyxoah | PairCorr |
0.84 | TMCI | Treace Medical Concepts | PairCorr |
Moving against Lantern Stock
0.43 | EYEN | Eyenovia | PairCorr |
0.38 | CRNX | Crinetics Pharmaceuticals | PairCorr |
0.43 | SGHT | Sight Sciences | PairCorr |
0.4 | PKX | POSCO Holdings | PairCorr |
0.34 | NHNCF | NAVER Corp | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Lantern Stock performing well and Lantern Pharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Lantern Pharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
TFFP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
GBIO | 3.57 | (1.12) | 0.00 | (2.24) | 0.00 | 6.74 | 17.22 | |||
LYRA | 2.59 | (0.04) | 0.00 | 0.09 | 0.00 | 5.56 | 25.31 | |||
IMNM | 3.28 | (0.36) | 0.00 | 1.09 | 0.00 | 7.03 | 20.87 | |||
CUE | 4.79 | 0.14 | 0.03 | 0.10 | 4.71 | 7.19 | 38.78 |
Lantern Pharma Corporate Management
DVM MS | CoFounder Advisor | Profile | |
Nicole Leber | Finance Associate | Profile | |
MS BS | Head Operations | Profile | |
Kishor Bhatia | Chief Consultant | Profile | |
Marc MD | Chief Therapeutics | Profile |